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Abstract 
Aims: Up to a third of patients with diabetes mellitus (DM) and heart failure (HF) are treated with 
insulin. As insulin causes sodium retention and hypoglycaemia, its use might be associated with worse 
outcomes. 
Methods and results: We examined two datasets: (1) 24,012 patients with HF from 4 large 
randomized trials and (2) an administrative database of 4 million individuals, 103857 with HF. In the 
former, survival was examined using Cox proportional hazards models adjusted for baseline variables 
and separately for propensity scores. Fine-Gray competing risk regression models were used to assess 
the risk of hospitalization for HF. For the latter a case-control nested within a population-based cohort 
study was conducted with propensity score. 
Prevalence of DM at study entry ranged from 25.5% to 29.5% across trials. Insulin alone or in 
combination with oral hypoglycaemic drugs was prescribed at randomization to 24.4% to 34.5% of 
the patients with diabetes. The rates of death from any cause and hospitalization for HF were higher in 
patients with diabetes vs no-diabetes, and highest of all in patients prescribed insulin (propensity 
score pooled HR for all-cause mortality 1.27 [1.16-1.38], for HF hospitalization 1.23 [1.13-1.33]). In the 
administrative registry, insulin prescription was associated with a higher risk of all-cause death (OR 
2.02 95% CI [1.87-2.19]) and re-hospitalization for HF (OR 1.42 95% CI [1.32-1.53]). 
Conclusions: Whether insulin use is associated with poor outcomes in HF should be investigated 
further with controlled trials, as should the possibility that there may be safer alternative glucose 
lowering treatments for patients with HF and T2DM. 
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Introduction 
The reciprocal relationship between type 2 diabetes mellitus (T2DM) and heart failure (HF) has long 
been recognized. T2DM is associated with a 2-fold higher risk of new-onset HF in males and up to a 5-
fold higher risk in females.1,2 Conversely, T2DM is present in 30-50% of all patients with HF, compared 
with approximately 20% of age- and sex-matched controls.3 Frank diabetes and pre-diabetic 
dysglycaemia are both associated with worse outcomes in HF.4-8 Although the benefits of standard 
treatments for HF are similar in patients with and without T2DM, the converse may not be true and 
there is much debate about how to safely achieve and maintain glycaemic control in HF patients with 
T2DM.9-11 Insulin remains a commonly used second line treatment in up to a third of patients with 
T2DM and HF. The safety of insulin in patients with HF and T2DM is unknown and there is concern 
that the sodium retaining action of this treatment12 along with the significant risk of hypoglycaemia 
could lead to worse outcomes than with other treatments.9,13-17 In the absence of a randomized trial, 
safety can only be assessed using observational data. The limitations of such non-randomized analyses 
are well known, including confounding by indication where prescription of insulin may be a marker of 
a more severe T2DM and HF.9,17 However, whether insulin is safe in HF is an important clinical 
question. Therefore, to address this question, we examined two complementary types dataset, while 
correcting as much as possible for confounding. Firstly, we analyzed 4 large randomized HF trials 
which enrolled 24,012 patients in more than 40 countries worldwide; these trials collected 
adjudicated outcomes over 2 to 4 years of follow-up, and biomarker data were available in 15,218 
patients. Secondly, we analyzed an administrative database including the 4 million people living in the 
Italian Region of Puglia. In this dataset patients with HF and diabetes were followed for 5 years. The 
database thus provided a large sample of “real world” patients, well characterized for diabetes 
duration and micro-and macro-vascular complications, treated in ordinary clinical practice to compare 
with the more selected patients enrolled in the clinical trials. 
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Methods 
Clinical trials 
Data from 4 independent large clinical trials were analyzed: the Valsartan Heart Failure Trial (Val-
HeFT),18 the Controlled Rosuvastatin Multinational Trial in HF (CORONA),19 the Gruppo Italiano per lo 
Studio della Sopravvivenza nell’Insufficienza Cardiaca – Heart Failure (GISSI-HF) trial,20 and the 
Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure (ATMOSPHERE).21 These trials, 
conducted over the last 20 years, were approved by the local ethics committees at each site, and all 
participants provided written informed consent. 
The Val-HeFT trial was a randomized, placebo-controlled, double-blind, parallel-arm multicentre trial 
that tested the efficacy of the angiotensin receptor antagonist valsartan on morbidity and mortality in 
5010 patients with stable, symptomatic HF with left ventricular systolic dysfunction.18 The CORONA 
trial randomized 5011 patients of at least 60 years of age with HF with left ventricular systolic 
dysfunction due to an ischemic etiology who were in New York Heart Association class II or higher, to 
rosuvastatin or placebo daily and assessed the effect on morbidity and mortality.19 GISSI-HF was a 
randomized, double-blind, placebo-controlled, multicenter trial that enrolled 6975 patients with 
clinical evidence of stable chronic HF, irrespective of the cause and the level of left ventricular ejection 
fraction (LVEF), and tested the effect of n-3 polyunsaturated fatty acids or rosuvastatin versus placebo 
on morbidity and mortality.20 In ATMOSPHERE, the ACE inhibitor enalapril was compared with the 
renin inhibitor aliskiren and with the combination of the two treatments in 7016 patients with HF and 
left ventricular systolic dysfunction on morbidity and mortality.21 
All events were adjudicated blindly by central endpoint committees in all trials. Two outcomes were 
used in the present analysis, all-cause mortality and first hospitalization for HF. 
Type of diabetes was available only for ATMOSPHERE: patients enrolled with T1DM were 2.3% out of 
1944 patients with diabetes. Given this very low prevalence of T1DM and assuming similar prevalence 
in the other 3 trials, the terms “T2DM” and “diabetes” will be used indifferently throughout the text. 
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Biomarkers 
At randomization, blood samples for biomarkers were collected and the plasma separated and stored 
at -70°C until analyzed blindly in central laboratories. N-terminal pro-B-type natriuretic peptide (NT-
proBNP), a marker of volume overload, was assayed in 3972 patients from Val-HeFT, 3664 from 
CORONA, 1231 from GISSI-HF, and 6351 from ATMOSPHERE, using a commercial assay (Roche 
Diagnostics, Basel, Switzerland). 
 
Administrative Registry 
We conducted a case-control study nested within a population-based cohort study, using a record-
linkage analysis of prescription databases, hospital discharge records, and the civil deaths registry. 
Data protection was assured by the Healthcare Agency of Puglia. All data were anonymised prior to 
being accessed by the authors and none of the authors were involved in data anonymisation. In Italy 
no ethical approval is required for aggregated-anonymous data. A cohort of subjects with HF were 
identified within the National Health Service Registry of the Puglia Region from 01/01/2008 to 
31/12/2013, to allow for at least 1 year of follow up (data available up to the end of 2014). HF was 
defined according to 2 criteria, hospitalization for HF or NHS-based exemption for disease 
(characteristic of the patients in Supplemental Tables 1 and 2). Within the cohort of patients with HF, 
the presence of diabetes was defined as at least one diagnosis of diabetes upon discharge from 
hospital, or NHS-based exemption for diabetes, or at least 2 prescriptions of hypoglycaemic drugs 
(ATC: A10) within 12 months from the index date. The relationship between insulin prescription and 
risk of death or first re-hospitalization for HF was assessed by a case-control (1:1) approach. For each 
year of observation (2008 through 2014) we identified cases, defined as subjects who were 
hospitalized for HF or had died, and matched controls. For HF hospitalization, a subject identified as 
case in one year could not be considered as a control in any subsequent year. 
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Statistical methods 
Categorical variables are presented as proportions, and continuous variables as means (SD) or 
medians (Q1–Q3), as appropriate. Differences in baseline clinical characteristics according to insulin 
prescription were compared by the Chi-Square test for categorical variables; for continuous variables, 
we used a t-test or nonparametric Kruskal–Wallis test. 
The associations between insulin prescription and pathophysiological and other characteristics were 
assessed as follows: congestion score by ordinal logistic regression model, furosemide prescription by 
a modified Poisson regression model, plasma concentrations of NT-proBNP by linear regression model 
on the natural logarithm of the values. For each outcome the model was, firstly, adjusted for baseline 
variables univariately associated (p < 0.05) with the outcome of interest (listed in Supplemental 
Methods 1), and, secondly, was adjusted with the propensity score according to the technique of 
Inverse Probability of Treatment Weighted (IPTW) that balances the relevant characteristics between 
insulin and non-insulin treated patients with diabetes. 
The propensity scores were estimated, for each outcome, by logistic regression models including all 
variables associated with the outcome of interest in univariable analyses. The ability of the propensity 
scores estimates to balance the clinical characteristics between the insulin and non-insulin treated 
patients was assessed with standardized differences and with the comparison of the empirical 
distribution function between the insulin groups. 
Kaplan–Meier survival analysis was performed by insulin prescription and compared by the log-rank 
test. Cox proportional hazards models were used to assess the risk of all-cause mortality. All models 
were adjusted for baseline variables that were associated with outcomes in univariable analysis at a 
level of p < 0.05 (listed in Supplemental Methods 2). Quantitative variables were fitted as a single 
continuous measurement; variables non-linearly distributed were log-transformed. These models 
were also adjusted with the propensity score, as previously described. Finally, Fine-Gray competing 
risk regression models, with or without propensity score adjustment, were used to assess the risk of 
hospitalization for HF where all-cause mortality was considered as competing event. 
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A two-sided P value lower than 0.05 was deemed significant. Statistical analyses were performed with 
SAS software, version 9.4 (SAS Institute, Cary, NC, USA). 
 
Meta-analyses of the results of the 4 trials were performed using Review Manager version 5.3 software 
(Nordic Cochrane Centre, Cochrane Collaboration). The pooled hazard ratio was estimated with 
generic inverse-variance method with fixed effect. Statistical heterogeneity was quantified using the I2 
statistic and homogeneity by the χ2 test. 
For the nested case-control analysis based on administrative databases, to reduce the bias in the 
comparison between patients with T2DM treated with insulin and those treated with other glucose 
lowering drugs, a propensity score–matching algorithm on a 1-to-1 basis was used. 
A logistic regression model including age, sex, presence of micro-vascular and macro-vascular 
complications, overall severity of co-morbid conditions, summarized by the Drug Derived Complexity 
Index (DDCI), previous hospitalization for arrhythmia, cancer, COPD, and chronic liver disease, year of 
the event and diabetes duration as covariates was used to predict the probability (propensity score) to 
receive insulin. The DDCI was previously shown to be a strong predictor of hospitalization, short term 
mortality, and long term mortality.22 A 8-to-1 greedy matching algorithm was used to identify a unique 
matched control for each case according to the propensity score. 
The relationships between insulin prescription and risk of death or risk of first re-hospitalization for 
HF were assessed through matched logistic regression analysis. 
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Results 
Clinical trials 
Clinical characteristics 
Prevalence of diagnosed diabetes at study entry was similar across the trials: 25.5% (1276/5010) in 
Val-HeFT, 29.5% (1477/5011) in CORONA, 28.3% (1974/6975) in GISSI-HF, and 27.7% (1944/7016) 
in ATMOSPHERE (Supplemental Table 1). Insulin alone or in combination with oral hypoglycaemic 
drugs was prescribed at randomization to these patients as follows: 34.5% (440/1276) in Val-HeFT, 
27.3% (403/1477) in CORONA, 27.5% (542/1974) in GISSI-HF, and to 24.4% (475/1944) in 
ATMOSPHERE (Supplemental Table 1). Age was similar for patients with and without diabetes and for 
patients with diabetes, irrespective of whether they received insulin. T2DM patients who received 
insulin were more likely to be women compared to T2DM patients not prescribed insulin and patients 
without diabetes. 
 
Markers of congestion 
Patients with diabetes treated with insulin had more severe heart failure than those not treated with 
insulin (Supplemental Table 1). In particular, a higher proportion were in NYHA functional class III or 
IV and they had a higher average creatinine and more signs of congestion, although these differences 
were not significant after multivariable adjustment (with or without propensity score matching, 
Supplemental Table 2). 
NT-proBNP levels were also higher in T2DM patients treated with insulin compared to T2DM patients 
not treated with insulin in Val-HeFT, CORONA and GISSI-HF (but not in ATMOSPHERE). Furosemide 
was prescribed more frequently to patients on insulin, compared to T2DM patients not prescribed 
insulin, in all 4 trials (Supplemental Tables 1 and 2). 
 
Clinical outcomes 
Mortality and HF hospitalization rates were higher in patients with diabetes compared to those 
without diabetes and were highest of all in those prescribed insulin (Table 1). Survival of patients with 
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diabetes prescribed insulin was consistently lower than in those not prescribed insulin (Supplemental 
Figure 1). 
Fully adjusted Cox multivariable models showed that insulin was independently associated with worse 
outcomes in 3 of the 4 trials, with similar trends in Val-HeFT (Table 2). Analysis using propensity score 
gave similar findings (Table 2). Meta-analysis of the 4 trials showed that insulin treatment was 
associated with a 32% higher adjusted risk of death and 23% higher risk of heart failure 
hospitalization, compared with non-insulin treatment of diabetes; the propensity score method gave 
similar findings (Figures 1 and 2). 
 
Administrative Registry 
In the Puglia Region, 103,857 individuals with heart failure, 39,631 (38.2%) of whom had diabetes, 
were identified with a mean age of 79.3±8.6 years. PPS matching led to the identification of 6,008 cases 
and 6,008 matched controls for the analysis of death, and 6,385 cases and an equal number of controls 
for re-hospitalization for HF (Supplemental Figure 2). Patients who died or were hospitalized for HF 
showed a similar profile of co-morbidities, whether they were on insulin or not (Supplemental Tables 
3 and 4). 
Logistic regression analysis showed that insulin prescription was associated with a significantly higher 
risk of all-cause death (OR 2.02 95% CI [1.87-2.19]) and re-hospitalization for HF (OR 1.42 95% CI 
[1.32-1.53]). 
 
Discussion 
The present analysis has several notable strengths, adding significantly to prior studies. Specifically, 
data were available from 4 large scale clinical trials providing a larger dataset than ever before and 
one in which all outcomes were adjudicated by independent committees. We had a “real-world” cohort 
of over 4 million citizens from the Puglia Region of Italy. Moreover, most patients had a measurement 
of NT-proBNP at randomization which allowed us to use it as an objective marker of congestion. 
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The principal and remarkably consistent finding, in both the clinical trials examined and in the 
administrative dataset, was that insulin treatment in HF was associated with a higher risk of death and 
of HF hospitalization, even after adjusting extensively for other predictors of adverse outcomes. These 
patients were at greater risk than not only individuals without diabetes but also those with diabetes 
treated with other glucose lowering drugs. 
It is well known that T2DM patients treated with insulin may be sicker and have a longer duration of 
diabetes which is of greater severity than in those not treated with insulin. These factors may be a 
major confounder in the assessment of the association between insulin use and adverse clinical 
outcomes. Duration of diabetes was recorded only in ATMOSPHERE and in the administrative Registry 
of Puglia. The estimates of risk in analyses adjusted for duration of diabetes were similar to those in 
analyses not adjusted for duration of diabetes in both ATMOSPHERE and the Puglia dataset. Therefore, 
information on duration of diabetes in the other trials is unlikely to change our conclusions about the 
risk related to insulin use, possibly because adjustment for co-morbidities and severity of diabetes 
reduced the uncontrolled bias of diabetes duration. 
Given that insulin may cause water and sodium retention,13,23 patients with T2DM treated with insulin 
might be expected to exhibit more signs of congestion, and higher circulating concentrations of NT-
proBNP, than individuals not treated with insulin. However, the differences in these variables 
disappeared after adjustment for the other characteristics of the patients (Supplemental Table 2). The 
rate of prescription of loop diuretics was significantly higher in patients treated with insulin, 
compared to those were not and this may have confounded the association with congestion. In relation 
to this, it is notable that greater use of diuretics is associated with worse outcomes in heart failure, 
although it is not known whether there is a causal relationship.24 
Sodium and water retention12 is not the only potential explanation for the worse outcomes associated 
with insulin use. Hypoglycaemia is more common in patients treated with insulin,25 and has several 
adverse cardiovascular effects such as adrenergic activation, tachycardia, myocardial ischemia, and 
hypokalemia, all potentially leading to lethal arrhythmias, as well as causing a pro-thrombotic 
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state.15,26 Indeed, if there is a causal relationship between insulin use and adverse outcomes, these 
alternative explanations may be more credible, given the modest difference in measures of congestion 
described above. 
One other potential adverse effect of insulin may also be relevant. Recent evidence suggests that 
insulin can inhibit cardiac contractility by inducing a Gi-biased 2-adrenergic signalling in hearts. 27 
There is one large scale randomized trial that might seem to contradict our findings (and those of 
others). In ORIGIN, 12,537 patients with cardiovascular risk factors plus impaired fasting glucose, 
impaired glucose tolerance, or type 2 diabetes were randomly assigned to insulin glargine or standard 
care. The incidence of hospital admission for HF was slightly but not significantly lower in the insulin 
glargine arm.28 However, this trial enrolled many patients without previously diagnosed diabetes and 
excluded patients with NYHA class III and IV HF at baseline. Therefore, most of the cases of HF 
identified during follow-up were incident and had an unknown phenotype. Baseline HbA1c was also 
quite low at 6.4%, as was the dose of insulin administered, potentially minimizing the risk of fluid 
retention and hypoglycaemia. 
Recently, the sodium glucose cotransporter 2 (SGLT-2)-inhibitor empaglifozin reduced the risk of incident 
HF and cardiovascular mortality, without a significant effect on myocardial infarction or stroke.
29,30
 
Cardiovascular benefits of the glucagon-like peptide 1 (GLP-1) analogues
31,32
 have been recently 
questioned.
33,34
 Although none of the GLP-1 agonist trials, or the SGLT2 inhibitor trial, enrolled many 
patients with HF, trials are underway in HF. 
The major limitation of the present study, common to all analyses of non-randomized treatments, is 
the inability to adjust for unmeasured confounders (and even to fully adjust for measured 
confounders). 35,36 Other specific limitations are the lack of information on type and dose of insulin, 
which may influence the risk of hypoglycaemia, HbA1c37, type of diabetes.Details of the oral 
hypoglycaemic drugs prescribed are available only for the Administrative Registry (see 
Supplementary Data, page ): this did not allow to assess potential confounders of insulin effect in the 4 
clinical trials. As most patients included in trials had HF with reduced LVEF (HFrEF), no inferences can 
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be made about patients with HF and preserved LVEF (HFpEF). The same information is not available 
from the Registry. However, a recent post-hoc analysis of the I-Preserve trial suggests that insulin use 
is also associated with a higher risk in patients with HFpEF.6 
In conclusion, insulin use is associated with higher risks of death and hospitalization for worsening of 
HF in T2DM patients with HFrEF, compared to T2DM patients with HFrEF not treated with insulin. 
This finding was seen consistently in 4 large clinical trials as well as in a “real world” population. 
Whether insulin use is associated with poor outcomes in HF should be investigated further with 
controlled trials, as should the possibility that there may be safer alternative glucose lowering 
treatments for patients with HF and T2DM. 
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Table 1. Incidence rates of adverse clinical outcomes in relation to diabetes and insulin prescription in the 4 clinical trials. 
 
Val-HeFT 
(n=5010 patients) 
CORONA 
(n=5011 patients) 
GISSI-HF 
(n=6975 patients) 
ATMOSPHERE 
(n=7016 patients) 
All patients 
(n=24012 patients) 
 Death 
HF 
hospitalization 
Death 
HF 
hospitalization 
Death 
HF 
hospitalization 
Death 
HF 
hospitalization 
Death 
HF 
hospitalizatio
n 
No diabetes 
9.8  
[9.1 - 10.5] 
8.0  
[7.4 - 8.7] 
11.1  
[10.5 - 11.85] 
10.4 
[9.7 - 11.1] 
7.3 
[6.9 - 7.6] 
8.1 
[7.6 - 8.5] 
8.4 
[8.0 - 8.8] 
6.0 
[5.6 - 6.4] 
8.7 
[8.4 – 8.9] 
7.7 
[7.5 – 8.0] 
Diabetes insulin NO 
11.4 
[9.7 - 13.1] 
12.2 
[10.3 - 14.0] 
13.0 
[11.7 - 14.4] 
14.3 
[12.8 - 16.0] 
8.8 
[8.0 - 9.7] 
11.4 
[10.4 - 12.4] 
10.4 
[9.5 - 11.3] 
8.3 
[7.5 - 9.1] 
10.4 
[9.9 – 11.0] 
10.9 
[10.3 – 11.4] 
Diabetes insulin YES 
14.6 
[11.9 - 17.2] 
17.0 
[13.9 - 20.0] 
16.4 
[14.0 - 19.2] 
19.1 
[16.3 - 22.5] 
13.9 
[12.1 - 15.6] 
18.6 
[16.2 - 20.9] 
13.1 
[11.4 - 15.0] 
12.6 
[10.9 - 14.7] 
14.7 
[13.6 – 15.7] 
16.5 
[15.2 – 17.7] 
 
Incidence Rate (95% CI) per 100 person-years.
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Table 2. Clinical outcomes by insulin prescription. 
 
Study 
N. of 
events/N. of 
pts 
Outcome Univariate Model Multivariable Model 
Multivariable Model with PS 
(IPTW) 
Val-HeFT 
293/1276 
All-cause Mortality 
1.28 [1.01-1.62], p=0.039 1.18 [0.93-1.50], p=0.175 1.23 [0.98 - 1.55], p=0.079 
HR [95% CI], p-value 
284/1276 
HF hospitalization* 
1.34 [1.06 – 1.71], p=0.0146 1.28 [0.96 – 1.70], p=0.0888 1.25 [0.97 – 1.61], p=0.0812 
HR [95% CI], p-value 
CORONA 
496/1477 
All-cause Mortality 
1.27 [1.05 - 1.53], p=0.014 1.28 [1.05 - 1.56], p=0.013 1.27 [1.05 - 1.53], p=0.014 
HR [95% CI], p-value 
467/1477 
HF hospitalization* 
1.28 [1.05-1.55], p=0.014 1.17 [0.96-1.42], p=0.129 1.14 [0.95-1.36], p=0.159 
HR [95% CI], p-value 
GISSI-HF 
675/1974 
All-cause Mortality 
1.58 [1.35 -1.85], p < 0.0001 1.54 [1.29 - 1.83], p < 0.0001 1.29 [1.10 -1.51], p=0.0014 
HR [95% CI], p-value 
712/1974 
HF hospitalization* 
1.35 [1.18 – 1.54], p <0.0001 1.18 [1.01 – 1.36], p=0.0319 1.20 [1.06 – 1.35], p=0.0036 
HR [95% CI], p-value 
ATMOSPHERE 
743/1944 
All-cause Mortality 
1.27 [1.08 - 1.49], p =0.004 1.25 [1.05 - 1.47], p=0.010 1.26 [1.09 - 1.45]‡, p=0.001 
HR [95% CI], p-value 
541/1944 
HF hospitalization* 
1.44 [1.20-1.73], p <0.001 1.36 [1.12-1.64], p=0.002 1.34 [1.14-1.58]^, p=0.001 
HR [95% CI], p-value 
 
Reference group for all hazard ratios (HR and 95% confidence intervals, CI) are diabetics without insulin prescription. 
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Covariates used for multivariable models are listed in the Supplemental Methods 2. 
IPTW= Inverse Probability of Treatment Weighted; PS=propensity score. 
*Fine-Gray competing risk regression models; ‡ when adjusted also for diabetes duration (<5 years and >=5 years), HR=1.21[1.05-1.39]; ^when adjusted also 
for diabetes duration (<5 years and >=5 years) HR=1.29[1.09-1.52].
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Figure 1. Forest plot: Insulin and all-cause mortality in diabetic patients with chronic HF.  
 
Figure 1.a. 
 
Figure 1.b. 
 
Caption Figure 1. Multivariable Cox model (1.a), and Multivariable Cox model adjusted by propensity 
score IPTW (Inverse Probability of Treatment Weighted) (1.b). Reference group for all hazard ratios 
(HR) are diabetics without insulin prescription. The size of the symbols corresponds to the weight 
assigned to each trial. Trials with lower variance of the risk estimate have higher weight.  
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Figure 2. Forest plot: Insulin and HF hospitalization in diabetic patients with chronic HF. 
Figure 2.a. 
 
Figure 2.b. 
 
Caption Figure 2. Fine-Gray competing risk regression model (2.a), and Fine-Gray competing risk 
regression model adjusted by propensity score IPTW (Inverse Probability of Treatment Weighted) 
(2.b). Reference group for all hazard ratios (HR) are diabetics without insulin prescription. The size of 
the symbols corresponds to the weight assigned to each trial. Trials with lower variance of the risk 
estimate have higher weight. 
